Baidu
map

BMC Neurol:卒中前用他汀可减少卒中严重度并促进患者早期功能恢复

2015-08-20 小田 译 医学论坛网

既往研究表明,卒中前他汀类药物治疗对缺血期和缺血损伤后神经恢复的神经保护具有双重影响。因此,韩国学者评估了卒中前应用他汀类药物对首次卒中严重度和早期临床转归的影响。 研究者分析了来自韩国12家医院8324例急性缺血性卒中患者的前瞻性数据。主要终点为美国国立卫生研究院卒中量表(NIHSS)评分下的首次卒中严重度。次要终点为出院时良好转归[改良Rankin量表(mRS)评分0-2分]和总

既往研究表明,卒中前他汀类药物治疗对缺血期和缺血损伤后神经恢复的神经保护具有双重影响。因此,韩国学者评估了卒中前应用他汀类药物对首次卒中严重度和早期临床转归的影响。

研究者分析了来自韩国12家医院8324例急性缺血性卒中患者的前瞻性数据。主要终点为美国国立卫生研究院卒中量表(NIHSS)评分下的首次卒中严重度。次要终点为出院时良好转归[改良Rankin量表(mRS)评分0-2分]和总mRS分布。利用多变量回归模型和匹配的倾向评分进行统计学分析。

结果卒中前应用他汀类药物的患者共有964例(11.6%)。统计分析结果显示,与卒中前未应用他汀类药物的患者相比,卒中前应用他汀类药物的患者初始NIHSS评分较低。卒中前应用他汀类药物与实现mRS 0-2的转归增加有关,还与总mRS分布的有利转变有关。

该研究表明,卒中前应用他汀类药物与即时卒中严重度减少独立相关,还与急性缺血性卒中患者早期功能恢复较佳有关。

原始出处:

Choi JC, Lee JS,et al.Effect of pre-stroke statin use on stroke severity and early functional recovery: a retrospective cohort study.BMC Neurol. 2015 Jul 30;15:120. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634122, encodeId=84881634122de, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Wed Dec 16 22:34:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974618, encodeId=15ad19e4618ac, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Oct 15 22:34:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999548, encodeId=ff9e1999548b3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 16 12:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599323, encodeId=5e781599323e3, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Aug 22 01:34:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634122, encodeId=84881634122de, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Wed Dec 16 22:34:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974618, encodeId=15ad19e4618ac, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Oct 15 22:34:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999548, encodeId=ff9e1999548b3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 16 12:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599323, encodeId=5e781599323e3, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Aug 22 01:34:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634122, encodeId=84881634122de, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Wed Dec 16 22:34:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974618, encodeId=15ad19e4618ac, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Oct 15 22:34:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999548, encodeId=ff9e1999548b3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 16 12:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599323, encodeId=5e781599323e3, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Aug 22 01:34:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2016-01-16 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1634122, encodeId=84881634122de, content=<a href='/topic/show?id=0e84211e53b' target=_blank style='color:#2F92EE;'>#严重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21175, encryptionId=0e84211e53b, topicName=严重度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcac22069264, createdName=zhangbaojun, createdTime=Wed Dec 16 22:34:00 CST 2015, time=2015-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974618, encodeId=15ad19e4618ac, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Oct 15 22:34:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999548, encodeId=ff9e1999548b3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 16 12:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599323, encodeId=5e781599323e3, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Sat Aug 22 01:34:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2015-08-22 mnda

相关资讯

Am J Cardiovasc Drugs:长期抗高血压治疗与卒中预防:荟萃分析

背景:每年卒中引起世界范围内约670万人死亡,是引起死亡的第二大疾病。高血压是卒中独立的危险因素,高血压药物治疗能显著降低卒中的发生率。虽然先前荟萃分析表明:一些抗高血压药物在降低卒中风险方面优于安慰剂,但是具体哪类药物是最有效的尚不清楚。方法:我们在MEDLINE进行系统性搜索1999年到2014年发表的抗高血压药物治疗对卒中一级和或二级预防的随机对照试验(RCT)的文章。五类抗高血压药物为:A

评“AHA/ASA 21世纪的卒中新定义专家共识”

作者:中山大学附属第一医院神经内科 苏镇培 黄如训来源:国际脑血管病杂志.2015,23(4):241-244——定义必须明晰,概念不可混淆2013年美国心脏协会(American Heart Association,AHA)/美国卒中协会(American Stroke Association,ASA)发表的“21世纪的卒中新定义”专家共识(以下简称“更新共识”)认为,当前关于卒中的定义,无

J Transl Med:血小板,性别和急性脑梗塞

目的:血小板在脑梗塞的发病机制中可能有着重要的意义。性别不同,血小板数量也不同。我们当前的工作是想确定卒中的男性和女性中,血小板活性是否不同。病人和方法:招募了73名患有急性缺血性脑梗塞的病人,其中女性病人32,男性病人42。包括各种卒中类型。应用电子计数血小板数量。应用流式细胞仪分析刺激后血小板表面粘附的纤维蛋白原以表示血小板的活性。应用ADP(1.7μmol/L)和一种凝血酶受体激动剂TRAP

Lancet:还在长时间的工作吗?小心增加卒中的风险

工作时间过长可能会增加心血管疾病的风险,但前瞻性的证据是稀缺的,不精确的,而且大多仅限于冠状动脉心脏疾病。该研究的目的是评估工作时间过长作为冠心病事件的心脏疾病和卒中的危险因素。研究人员通过PubMed和Embase从成立到2014年8月20日确定了已发表的研究。研究人员在工作人群(IPD工作)联盟的单个参与者-数据Meta分析获得了未发表的20个队列研究的数据和开放的数据档案。研究人员采用累积随

Stroke:卒中后的运动康复治疗的药物

在卒中后所有在研究的治疗措施中能够改善患者长期预后的是那些针对性康复的药物。这些药物与卒中后促进神经保护或者改善患者再灌注是不同的。促进康复的药物与卒中后可塑性和生长相关,一般来说,主要是运动的改善而不是梗死体积的减少。针对康复的干预有时间窗,有时是几天或者几周或者月,也就是说,卒中后大部分病人可以应用。目前,在改善患者卒中后运动康复的药物中,5-羟色胺和多巴胺能药物被充分证据证明。相比其他针对动

CSPPT试验启示:用中国的循证指导中国的卒中一级预防临床实践

近期,一项由中外知名医学专家共同参与的中国脑卒中一级预防研究(CSPPT)结果在美国加利福尼亚州圣迭戈市举行的美国心脏病学会2015年度科学会议上公布,并在世界著名医学杂志《美国医学会杂志》上同步发表(JAMA:叶酸补充剂可减低高血压患者脑卒中的危险性(CSPPT试验))。随后,在5月9日的中国脑卒中大会上进行了“CSPPT重大科研成果新闻发布会”。CSPPT研究探索出一条有中国特色的心血管防治之

Baidu
map
Baidu
map
Baidu
map